Lepu Biopharma Co., Ltd. (2157.HK)
HKD 3.31
(0.91%)
HKD 3.31
(0.91%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -250.83 Million | -480.92 Million | -621.73 Million | -422.68 Million | -233.99 Million |
| Net Income | -30.3 Million | -699.44 Million | -1.02 Billion | -613.44 Million | -515.49 Million |
| Depreciation & Amortization | 102.57 Million | 95.44 Million | 95.24 Million | 84.11 Million | 49.26 Million |
| Deferred income taxes | - | 39.61 Million | 11.55 Million | 11.77 Million | 7.33 Million |
| Stock-based compensation | 18.57 Million | 30.41 Million | 113.5 Million | 5.22 Million | 143.69 Million |
| Change in working capital | 11.69 Million | 28.66 Million | 109.57 Million | -68.9 Million | -9.03 Million |
| Other non-cash items | -168.52 Million | 24.36 Million | 77.24 Million | 158.55 Million | 90.23 Million |
| Investing Cash Flow | 18.25 Million | -74.66 Million | -3.89 Million | -749.66 Million | -415.31 Million |
| Investments in PPE | -41.19 Million | -110.45 Million | -213.38 Million | -301.82 Million | -318.47 Million |
| Acquisitions | 59.31 Million | -10 Million | -90 Million | -94.56 Million | -60 Million |
| Investment purchases | -50 Million | -52 Million | -1.18 Billion | -1.68 Billion | -554.86 Million |
| Sales/Maturities of investments | 50.13 Million | 97.78 Million | 1.48 Billion | 1.33 Billion | 511.53 Million |
| Other Investing Activities | 111.93 Million | 45.78 Million | 309.49 Million | 771 Thousand | 6.48 Million |
| Financing Cash Flow | -11.01 Million | 1.03 Billion | 380.31 Million | 1.38 Billion | 770.39 Million |
| Debt repayment | -44.24 Million | -80.97 Million | -500 Thousand | -80 Million | -36.09 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | 739.22 Million | - | - | - |
| Other Financing Activities | -30.57 Million | 373.71 Million | 380.81 Million | 1.46 Billion | 806.48 Million |
| Accounts receivables | -38.01 Million | 25.98 Million | -20.36 Million | -76.14 Million | -46.35 Million |
| Accounts payables | - | -25.98 Million | 20.36 Million | 76.14 Million | 46.35 Million |
| Inventory | -5.35 Million | 123 Thousand | -4.61 Million | -11.48 Million | -8.08 Million |
| Other working capital | 5.03 Million | 28.54 Million | 114.19 Million | -57.42 Million | -956 Thousand |
| Cash at beginning of period | 669.39 Million | 155.16 Million | 402.86 Million | 188.54 Million | 67.46 Million |
| Cash at end of period | 426.01 Million | 669.39 Million | 155.16 Million | 402.86 Million | 188.54 Million |
| Capital Expenditure | -41.19 Million | -110.45 Million | -213.38 Million | -301.82 Million | -318.47 Million |
| Effect of forex changes on cash | 212 Thousand | 37.85 Million | -2.38 Million | 1000.00 | 1000.00 |
| Net cash flow / Change in cash | -243.38 Million | 514.22 Million | -247.69 Million | 214.32 Million | 121.08 Million |
| Free Cash Flow | -292.03 Million | -591.37 Million | -835.12 Million | -724.51 Million | -552.46 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -103.38 Million | -104.27 Million | 65.9 Million | -30.3 Million | 64.25 Million | -160.48 Million |
| Depreciation & Amortization | 26.32 Million | 26.54 Million | 27.05 Million | 102.57 Million | 26.37 Million | 58.28 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 455.59 Thousand | 459.52 Thousand | 8.98 Million | 18.57 Million | 8.76 Million | - |
| Change in working capital | - | - | -21.08 Million | 11.69 Million | -20.55 Million | - |
| Other non-cash items | 14.75 Million | 14.88 Million | -177.24 Million | -168.52 Million | -172.8 Million | 116.11 Million |
| Investing Cash Flow | -12.68 Million | -12.79 Million | 57.85 Million | 18.25 Million | 56.4 Million | -98.29 Million |
| Investments in PPE | -6.53 Million | -6.58 Million | -5.6 Million | -41.19 Million | -5.45 Million | -24.78 Million |
| Acquisitions | - | - | -374.59 Thousand | 59.31 Million | -365.2 Thousand | -73.51 Million |
| Investment purchases | - | - | -54.01 Million | -50 Million | - | - |
| Sales/Maturities of investments | - | - | 189.2 Million | 50.13 Million | - | - |
| Other Investing Activities | -6.15 Million | -6.21 Million | 63.82 Million | 111.93 Million | 62.22 Million | - |
| Financing Cash Flow | 121.41 Million | 122.45 Million | -46.79 Million | -11.01 Million | -45.62 Million | 100.92 Million |
| Debt repayment | -38.28 Million | - | -64.51 Million | -44.24 Million | - | -112.31 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 227.49 Million | - | -1.29 Million | - | - | - |
| Other Financing Activities | 121.41 Million | 122.45 Million | -46.79 Million | -30.57 Million | -45.62 Million | -11.39 Million |
| Accounts receivables | - | - | -20.91 Million | -38.01 Million | -20.38 Million | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | -2.94 Million | -5.35 Million | -2.86 Million | - |
| Other working capital | - | - | 2.76 Million | 5.03 Million | 2.69 Million | - |
| Cash at beginning of period | 469.04 Million | - | 627.29 Million | 669.39 Million | 627.96 Million | 751.55 Million |
| Cash at end of period | 551.9 Million | 47.48 Million | 469.04 Million | 426.01 Million | 544.6 Million | 627.29 Million |
| Capital Expenditure | -6.53 Million | -6.58 Million | -5.6 Million | -41.19 Million | -5.45 Million | -24.78 Million |
| Effect of forex changes on cash | 208.99 Thousand | 210.79 Thousand | -168.32 Thousand | 212 Thousand | -164.1 Thousand | -24.22 Million |
| Net cash flow / Change in cash | 82.86 Million | 47.48 Million | -158.24 Million | -243.38 Million | -83.36 Million | -124.26 Million |
| Free Cash Flow | -68.38 Million | -68.97 Million | -101.99 Million | -292.03 Million | -99.43 Million | -127.44 Million |
TPS
TIG
002728
8957
ISUR
600572